Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist J.C. Walter Jr. Transplant Center - Houston, TX

Current/On-going Research

Dr. Osama Gaber

Total: 18 projects

  1. Source: NIAID
    Type: Clinical Study Grant
    Title: B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop de novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection
    PI: Mohammed Sayegh, M.D.
    Dates: Oct 2007-Jan 2010

  2. Source: NIAID
    Type: Clinical Study Grant (R34 Planning Grant)
    Title: Effect of Dietary Supplements in African American Kidney Transplant Recipients
    PI: A. Osama Gaber, M.D.
    Dates: Sep 2007-Jan 2009

  3. Source: Novartis
    Type: Clinical Study Grant
    Title: A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de novo liver transplant recipients
    PI: A. Osama Gaber, M.D.
    Dates: May 2008-May 2009

  4. Source: Novartis
    Type: Clinical Study Grant
    Title: A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic® vs. a standard dosing regiment of Myfortic® in combination with Neoral® and Corticosteroids in de novo renal transplant patients
    PI: A. Osama Gaber, M.D.
    Dates: Dec 2007-Mar 2009

  5. Source: LifeCycle Pharma
    Type: Clinical Study Grant
    Title: A phase II, open-label, multi-center prospective, conversion study in stable liver transplant patients to compare the pharmacokinetics of LCP-Tacro tablets once-a-day to Prograf® capsules twice-a-day
    PI: A. Osama Gaber, M.D.
    Dates: Jun 2007-Jan 2009

  6. Source: LifeCycle Pharma
    Title: A phase 2, open-label, multi-center, randomized trial to demonstrate the pharmacokinetics ofLCP-Tacro tablets once daily and Prograf® capsules twice daily in adult de novo kidney transplant patients
    PI: A. Osama Gaber, M.D.
    Dates: Oct 2008-Mar 2010

  7. Source: LifeCycle Pharma
    Title: A phase 2, open-label, multi-center, randomized trial to demonstrate the pharmacokinetics of LCP-Tacro tablets once daily and Prograf® capsules twice daily in adult de novo liver
    t ransplant patients
    PI: A. Osama Gaber, M.D.
    Dates: Nov 2008-Apr 2010

  8. Source: Hoffman LaRoche
    Type: Clinical Study Grant
    Title: A double-blind, randomized, placebo controlled, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza.
    PI: A. Osama Gaber, M.D.
    Dates: Aug 2007-Jul 2009

  9. Source: Viropharma
    Type: Clinical Study Grant
    Title: A randomized, double-blind study to assess the efficacy and safety of prophylactic use of Marivabar versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants.
    PI: A. Osama Gaber, M.D.
    Dates: Nov 2007-Apr 2009

  10. Source: Wyeth
    Type: Clinical Study Grant
    Title: A randomized, placebo controlled, double-blind comparative study evaluating the effect of Ramipril on urinary protein excretion in maintenance renal transplant patients converted to Sirolimus.
    PI: A. Osama Gaber, M.D.
    Dates: May 2008-May 2010

  11. Source: Astellas
    Type: Clinical Study Grant
    Title: A Phase II, proof of concept, randomized, open-label, two arm, parallel group, multi-center study to assess the safety of efficacy FK778 compared with standard care in renal transplant recipients with untreated biopsy-diagnosed BK neuropathy
    PI: A. Osama Gaber, M.D.
    Dates: 2003-2016

  12. Source: Astellas
    Type: Clinical Study Grant
    Title: A Phase II, randomized, open-label, parallel group, multi-center study to assess the safety of efficacy Prograf/FK778 and Prograf/MMF in de novo kidney transplant recipients
    PI: A. Osama Gaber, M.D.
    Dates: 2004-2008

  13. Source: Immune Tolerance Network and National Institute of Allergic and Infectious Disease
    Type: Clinical Study Grant
    Title: A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campth-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation
    PI: A. Osama Gaber, M.D.
    Dates: 2004-2010

  14. Source: LifeCycle Pharma
    Type: Clinical Study Grant
    Title: A phase II, open-label, multi-center prospective, conversion study in stable kidney transplant patients to compare the pharmacokinetics of LCP-Tacro tablets once-a-day to Prograf® capsules twice-a-day
    PI: A. Osama Gaber, M.D.
    Dates: 2007-2008

  15. Source: Hoffman LaRoche
    Type: Clinical Study Grants
    Title: A double-blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients with influenza
    PI: A. Osama Gaber, M.D.
    Dates: 2007-2008

  16. Source: Y’s Therapeutics
    Type: Clinical Study Grant
    Title: A controlled, randomized, prospective, double-blind, multi-center, phase I/II, intravenous, single-dose, dose-escalation study of the safety, pharmacokinetics, and efficacy of YSPSL for prevention of delayed graft funtionc in patients undergoing cadaveric kidney transplantation, YSPSL.
    PI: A. Osama Gaber, M.D.
    Dates: 2006-2008

  17. Source: Isotechnika, Inc.
    Type: Clinical Study Grant
    Title: A PhaseII, randomized, multicenter, open-label, concentration controlled, safety study of ISA247 and tacrolimus (Prograf) in denovo renal transplant patients
    PI: A. Osama Gaber, M.D.
    Dates: 2005-2008

  18. Source: Roche
    Type: Clinical Study Grant
    Title: An open label randomized, multicenter study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on mycophenolate mofetil; (Cellcept) and Sirolimus (Rapammune)
    PI: A. Osama Gaber, M.D.
    Dates: 2003-2008